The sigma-1 receptor agonist fluvoxamine alleviates endotoxin-induced acute lung injury in mice
Frontiers in Pharmacology · 28.04.2026 · 17
DOI: 10.3389/fphar.2026.1818198 ↗Kurz gefasst
Fachartikel in der Zeitschrift Frontiers in Pharmacology, online erschienen am 28.04.2026. Verfasst von Emese Ritter und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacology and Pharmacotherapy, University of Pécs, Medical School, Pécs, Hungary. Die Arbeit nennt 33 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Introduction
Acute lung inflammation has recently gained increasing attention due to the high acute respiratory distress syndrome complications with subsequent fibrosis during the COVID-19 pandemic. Our group identified that the antifibrotic effect of the antidepressant fluvoxamine (FLU) in various organs is meditated via sigma-1 receptor (S1R) agonism. Since the actions of FLU on the inflammatory components have not been elucidated, this study investigated its effects in a mouse model of interstitial pneumonitis.
Methods
Pneumonitis was induced in wild-type (WT) and S1R knockout ( S1r −/− ) mice by intratracheal administration of lipopolysaccharide: 0.5 mg/kg LPS. Treatment groups were randomized into 1) phosphate-buffered saline (PBS) +vehicle, 2) LPS + vehicle, 3) LPS + FLU ( i.p. 20 mg x bwkg -1 ) or 4) LPS + dexamethasone ( i.p. 5 mg x bwkg -1 ) groups.
Results
LPS reduced tidal volume, minute ventilation, peak expiratory, inspiratory and mid-tidal expiratory flows. Similarly to the reference compound dexamethasone FLU counteracted all effects in WT, but not in S1r −/− mice. Furthermore, FLU alleviated LPS-induced macrophage infiltration in both genotypes, but had no effect on lung edema or neutrophil accumulation. FLU downregulated inflammatory cytokines IL-1, IL-6, TNF-α, and MCP-1 in WT mice , similarly to dexamethasone, but not in S1r −/− mice.
Conclusion
Overall, FLU mitigates LPS-induced pulmonary inflammation and functional deterioration primarily via S1R signaling, highlighting a receptor-specific mechanism underlying its protective effects. Thus, targeting S1R may be an effective and safe alternative to other therapeutic approaches, including glucocorticoids to treat inflammatory lung injury.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Pharmacology and Pharmacotherapy, University of Pécs, Medical School, Pécs, Hungary.
- National Laboratory for Drug Research and Development, Budapest, Hungary.
- MTA-SE Lendület "Momentum" Diabetes Research Group, Budapest, Hungary.
- Pediatric Center, Semmelweis University, Budapest, Hungary.
- Department of Pathology and Experimental Cancer Research, Semmelweis University, Faculty of Medicine, Budapest, Hungary.
- Department of Pathology, University of Pécs, Medical School, Pécs, Hungary.
Zitieren
APA
Ritter, E., Csekő, K., Hosszú, Á., Tóth, Á. R., Hargitai, D., Kereskai, L., Fekete, A., & Helyes, Z. (2026). The sigma-1 receptor agonist fluvoxamine alleviates endotoxin-induced acute lung injury in mice. Frontiers in Pharmacology, 17. https://doi.org/10.3389/fphar.2026.1818198
Vancouver
Ritter E, Csekő K, Hosszú Á, Tóth ÁR, Hargitai D, Kereskai L, et al. The sigma-1 receptor agonist fluvoxamine alleviates endotoxin-induced acute lung injury in mice. Frontiers in Pharmacology. 2026;17. doi:10.3389/fphar.2026.1818198
BibTeX
@article{Ritter2026,
author = {Ritter, Emese and Csekő, Kata and Hosszú, Ádám and Tóth, Ákos R and Hargitai, Dóra and Kereskai, László and Fekete, Andrea and Helyes, Zsuzsanna},
title = {The sigma-1 receptor agonist fluvoxamine alleviates endotoxin-induced acute lung injury in mice},
journal = {Frontiers in Pharmacology},
year = {2026},
volume = {17},
doi = {10.3389/fphar.2026.1818198}
}
EUVIMED